Wasatch Advisors Inc. Buys Shares of 25,771 Glaukos Corp (GKOS)

Wasatch Advisors Inc. purchased a new stake in Glaukos Corp (NYSE:GKOS) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 25,771 shares of the medical instruments supplier’s stock, valued at approximately $661,000. Wasatch Advisors Inc. owned 0.07% of Glaukos at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Ameritas Investment Partners Inc. grew its holdings in shares of Glaukos by 93.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 1,212 shares during the period. Valeo Financial Advisors LLC purchased a new position in Glaukos in the 3rd quarter worth approximately $111,000. BNP Paribas Arbitrage SA boosted its holdings in Glaukos by 740.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock worth $147,000 after acquiring an additional 3,118 shares during the period. Quantbot Technologies LP boosted its holdings in Glaukos by 291.3% in the 3rd quarter. Quantbot Technologies LP now owns 7,653 shares of the medical instruments supplier’s stock worth $252,000 after acquiring an additional 5,697 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in Glaukos in the 2nd quarter worth approximately $262,000.

In other Glaukos news, CFO Joseph E. Gilliam purchased 2,100 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The stock was bought at an average price of $23.84 per share, with a total value of $50,064.00. Following the completion of the purchase, the chief financial officer now owns 102,100 shares in the company, valued at approximately $2,434,064. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 16.40% of the company’s stock.

A number of brokerages have issued reports on GKOS. BMO Capital Markets reaffirmed a “buy” rating on shares of Glaukos in a research report on Monday, December 11th. Cantor Fitzgerald set a $48.00 target price on Glaukos and gave the company a “buy” rating in a research report on Wednesday, December 27th. Zacks Investment Research raised Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, November 13th. Stephens reissued an “overweight” rating and set a $40.00 price target (down from $47.00) on shares of Glaukos in a research report on Monday, November 13th. Finally, ValuEngine lowered Glaukos from a “hold” rating to a “sell” rating in a research report on Monday, February 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Glaukos currently has an average rating of “Buy” and a consensus target price of $44.86.

Glaukos Corp (GKOS) traded up $0.28 during trading hours on Monday, hitting $29.34. The stock had a trading volume of 199,046 shares, compared to its average volume of 473,317. Glaukos Corp has a 12 month low of $23.08 and a 12 month high of $52.49. The company has a market capitalization of $1,004.47, a PE ratio of -733.32, a price-to-earnings-growth ratio of 42.12 and a beta of 1.21.

TRADEMARK VIOLATION NOTICE: This report was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.thelincolnianonline.com/2018/02/12/wasatch-advisors-inc-invests-661000-in-glaukos-corp-gkos-updated-updated-updated.html.

Glaukos Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply